Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

463
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
463

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early-Onset Severe Liver Fibrosis in a Toddler with Erythropoietic Protoporphyria Associated with Rare Compound Heterozygous FECH Variants.

Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society·2026
Same author

Evaluating mesothelin as an immunotherapeutic target for endogenous T cells.

Frontiers in immunology·2026
Same author

Disease-dependent airway epithelial responses to acute electronic cigarette aerosol exposure: a pilot single-cell analysis.

Toxicological sciences : an official journal of the Society of Toxicology·2026
Same author

Loss of tumor suppressor NF2 mediates resistance to CAR T cell and anti-PD-1 therapy: Strategies to restore immunotherapy sensitivity.

Med (New York, N.Y.)·2026
Same author

Malignancy-mimicking Kayexalate-associated extraintestinal mass and literature review.

Clinical journal of gastroenterology·2026
Same author

CN-RNN: a Deep Learning Framework for Copy Number Variation Detection with Exome Sequencing Data.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: May 27, 2025

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

11.0K

Tumor Immune Microenvironment Differences Associated With Racial Disparities in Pancreatic Cancer.

Zachary Gao1, Joseph Azar2, Derek Erstad3

  • 1Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.

The Journal of Surgical Research
|February 19, 2025
PubMed
Summary

African American and European American pancreatic cancer patients show distinct molecular differences, including TP53 mutations and immune gene expression. These disparities may explain survival differences in pancreatic adenocarcinoma (PDAC).

Keywords:
African AmericanEuropean AmericanNanoStringPancreatic adenocarcinomaPancreatic cancerRacial disparities in Cancer

More Related Videos

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity
06:16

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity

Published on: December 7, 2019

12.5K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

574

Related Experiment Videos

Last Updated: May 27, 2025

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

11.0K
Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity
06:16

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity

Published on: December 7, 2019

12.5K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

574

Area of Science:

  • Oncology
  • Genomics
  • Immunology

Background:

  • Racial disparities in antitumoral immunity are observed across cancers, potentially impacting survival.
  • Limited research exists on molecular differences in pancreatic adenocarcinoma (PDAC) between racial groups.
  • African American (AA) and European American (EA) PDAC patients may experience different biological mechanisms contributing to survival gaps.

Purpose of the Study:

  • To investigate molecular and biological differences between AA and EA PDAC patients.
  • To identify potential drivers of racial disparities in pancreatic cancer survival.
  • To explore genetic mutations and immune gene expression variations based on race.

Main Methods:

  • Analysis of genomic PDAC mutational data stratified by race.
  • Tissue microarray and multiplex gene expression analysis (NanoString) on surgical PDAC specimens.
  • Comparison of TP53 mutations and immunologic gene annotations between AA and EA cohorts.

Main Results:

  • AA PDAC patients exhibited significantly higher rates of TP53 mutations compared to EA patients (4679 samples analyzed).
  • Significant differences in immunologic gene annotations were found between AA and EA groups (P < 0.05).
  • Tissue microarray included 12 AA and 41 EA treatment-naive PDAC samples.

Conclusions:

  • Molecular and microenvironmental distinctions exist between AA and EA PDAC patients.
  • These identified differences may contribute to observed racial survival disparities in pancreatic cancer.
  • Understanding these molecular variations is crucial for improving outcomes for AA PDAC patients.